Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

Prognostic value of 1p/19q chromosomal codeletion in patients with oligodendroglioma.

Laghari AA, Khalid MU, Qadeer N, Shamim MS.

J Pak Med Assoc. 2019 Jan;69(1):132-134.

2.

Alpha internexin expression related with molecular characteristics in adult glioblastoma and oligodendroglioma.

Suh JH, Park CK, Park SH.

J Korean Med Sci. 2013 Apr;28(4):593-601. doi: 10.3346/jkms.2013.28.4.593. Epub 2013 Mar 27.

3.

The Correlation Between 1p/19q Codeletion, IDH1 Mutation, p53 Overexpression and Their Prognostic Roles in 41 Turkish Anaplastic Oligodendroglioma Patients.

Hacisalihoglu P, Kucukodaci Z, Gundogdu G, Bilgic B.

Turk Neurosurg. 2017;27(5):682-689. doi: 10.5137/1019-5149.JTN.16832-15.1.

4.

Prognostic significance of relative 1p/19q codeletion in oligodendroglial tumors.

Chamberlain MC, Born D.

J Neurooncol. 2015 Nov;125(2):249-51. doi: 10.1007/s11060-015-1906-y. Epub 2015 Sep 4.

PMID:
26341371
5.

Polysomy for chromosomes 1 and 19 predicts earlier recurrence in anaplastic oligodendrogliomas with concurrent 1p/19q loss.

Snuderl M, Eichler AF, Ligon KL, Vu QU, Silver M, Betensky RA, Ligon AH, Wen PY, Louis DN, Iafrate AJ.

Clin Cancer Res. 2009 Oct 15;15(20):6430-7. doi: 10.1158/1078-0432.CCR-09-0867. Epub 2009 Oct 6.

6.

Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience.

Frenel JS, Leux C, Loussouarn D, Le Loupp AG, Leclair F, Aumont M, Mervoyer A, Martin S, Denis MG, Campone M.

J Neurooncol. 2013 Aug;114(1):85-91. doi: 10.1007/s11060-013-1152-0. Epub 2013 May 17.

PMID:
23681562
7.

[Diagnostic and prognostic values of 1p and 19q deletions in adult gliomas: critical review of the literature and implications in daily clinical practice].

Fontaine D, Vandenbos F, Lebrun C, Paquis V, Frenay M.

Rev Neurol (Paris). 2008 Jun-Jul;164(6-7):595-604. doi: 10.1016/j.neurol.2008.04.002. Epub 2008 May 21. Review. French.

PMID:
18565359
8.

Clinical significance of chromosome 1p/19q loss of heterozygosity and Sox17 expression in oligodendrogliomas.

Li J, Miao N, Liu M, Cui W, Liu X, Li X, Shi X, Qing S, Ma Y, Zhang W, Biekemituofu H.

Int J Clin Exp Pathol. 2014 Dec 1;7(12):8609-15. eCollection 2014.

9.

Application of brush cytology for FISH-based detection of 1p/19q codeletion in oligodendroglial tumors.

Srebotnik-Kirbiš I, Limbäck-Stokin C.

J Neurooncol. 2016 Sep;129(3):415-422. doi: 10.1007/s11060-016-2211-0. Epub 2016 Jul 12.

PMID:
27406587
10.

Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features.

van den Bent MJ, Looijenga LH, Langenberg K, Dinjens W, Graveland W, Uytdewilligen L, Sillevis Smitt PA, Jenkins RB, Kros JM.

Cancer. 2003 Mar 1;97(5):1276-84.

11.

Integrated analysis identified genes associated with a favorable prognosis in oligodendrogliomas.

Liu Y, Hu H, Zhang C, Wang Z, Li M, Jiang T.

Genes Chromosomes Cancer. 2016 Feb;55(2):169-76. doi: 10.1002/gcc.22323. Epub 2015 Nov 6.

PMID:
26542540
12.

Ancillary FISH analysis for 1p and 19q status: preliminary observations in 287 gliomas and oligodendroglioma mimics.

Perry A, Fuller CE, Banerjee R, Brat DJ, Scheithauer BW.

Front Biosci. 2003 Jan 1;8:a1-9.

PMID:
12456321
13.

Tumour necrosis and microvascular proliferation are associated with 9p deletion and CDKN2A alterations in 1p/19q-deleted oligodendrogliomas.

Godfraind C, Rousseau E, Ruchoux MM, Scaravilli F, Vikkula M.

Neuropathol Appl Neurobiol. 2003 Oct;29(5):462-71.

PMID:
14507338
14.

High Carbonic Anhydrase-9 Expression Identifies a Subset of 1p/19q Co-Deletion and Favorable Prognosis in Oligodendroglioma.

Sathornsumetee S, Cheunsuchon P, Sangruchi T.

World Neurosurg. 2016 Jul;91:518-523.e1. doi: 10.1016/j.wneu.2016.02.069. Epub 2016 Mar 4.

PMID:
26960282
15.

The importance of 10q status in an outcomes-based comparison between 1p/19q fluorescence in situ hybridization and polymerase chain reaction-based microsatellite loss of heterozygosity analysis of oligodendrogliomas.

Horbinski C, Nikiforova MN, Hobbs J, Bortoluzzi S, Cieply K, Dacic S, Hamilton RL.

J Neuropathol Exp Neurol. 2012 Jan;71(1):73-82. doi: 10.1097/NEN.0b013e318240fa65.

16.

Mitotic index, microvascular proliferation, and necrosis define 3 groups of 1p/19q codeleted anaplastic oligodendrogliomas associated with different genomic alterations.

Figarella-Branger D, Mokhtari K, Dehais C, Jouvet A, Uro-Coste E, Colin C, Carpentier C, Forest F, Maurage CA, Vignaud JM, Polivka M, Lechapt-Zalcman E, Eimer S, Viennet G, Quintin-Roué I, Aubriot-Lorton MH, Diebold MD, Loussouarn D, Lacroix C, Rigau V, Laquerrière A, Vandenbos F, Michalak S, Sevestre H, Peoch M, Labrousse F, Christov C, Kemeny JL, Chenard MP, Chiforeanu D, Ducray F, Idbaih A; POLA Network.

Neuro Oncol. 2014 Sep;16(9):1244-54. doi: 10.1093/neuonc/nou047. Epub 2014 Apr 9.

17.

IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.

van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoorn MJ, Wesseling P, Frenay M, Tijssen CC, Lacombe D, Idbaih A, van Marion R, Kros JM, Dinjens WN, Gorlia T, Sanson M.

Clin Cancer Res. 2010 Mar 1;16(5):1597-604. doi: 10.1158/1078-0432.CCR-09-2902. Epub 2010 Feb 16.

18.

Histological spectrum of oligodendroglial tumors: Only a subset shows 1p/19q codeletion.

Pai T, Epari S, Desai S, Wadile A, Gupta T, Goda JS, Moiyadi A, Shetty P, Kane S, Jalali R.

Neurol India. 2017 Jan-Feb;65(1):113-120. doi: 10.4103/0028-3886.198195.

19.

A "weighted" fluorescence in situ hybridization strengthens the favorable prognostic value of 1p/19q codeletion in pure and mixed oligodendroglial tumors.

Senetta R, Verdun di Cantogno L, Chiusa L, Castellano I, Gugliotta P, Sapino A, Cassoni P.

J Neuropathol Exp Neurol. 2013 May;72(5):432-41. doi: 10.1097/NEN.0b013e3182901f41.

20.

Oligodendrogliomas: molecular biology and treatment.

Bromberg JE, van den Bent MJ.

Oncologist. 2009 Feb;14(2):155-63. doi: 10.1634/theoncologist.2008-0248. Epub 2009 Jan 31. Review.

Supplemental Content

Support Center